BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23190520)

  • 1. High prevalence of anti-apolipoprotein/A-1 autoantibodies in maintenance hemodialysis and association with dialysis vintage.
    Pruijm M; Schmidtko J; Aho A; Pagano S; Roux-Lombard P; Teta D; Burnier M; Vuilleumier N
    Ther Apher Dial; 2012 Dec; 16(6):588-94. PubMed ID: 23190520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex.
    Pagano S; Satta N; Werling D; Offord V; de Moerloose P; Charbonney E; Hochstrasser D; Roux-Lombard P; Vuilleumier N
    J Intern Med; 2012 Oct; 272(4):344-57. PubMed ID: 22329401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-apolipoprotein A-1 autoantibodies as biomarker for atherosclerosis burden in patients with periodontitis.
    Wick PA; Mombelli A; Pagano S; Moren X; Giannopoulou C; Mach F; Roux-Lombard P; Vuilleumier N
    J Periodontal Res; 2013 Jun; 48(3):350-6. PubMed ID: 23050768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability.
    Montecucco F; Vuilleumier N; Pagano S; Lenglet S; Bertolotto M; Braunersreuther V; Pelli G; Kovari E; Pane B; Spinella G; Pende A; Palombo D; Dallegri F; Mach F; Roux-Lombard P
    Eur Heart J; 2011 Feb; 32(4):412-21. PubMed ID: 21224292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis.
    Vuilleumier N; Bas S; Pagano S; Montecucco F; Guerne PA; Finckh A; Lovis C; Mach F; Hochstrasser D; Roux-Lombard P; Gabay C
    Arthritis Rheum; 2010 Sep; 62(9):2640-50. PubMed ID: 20506304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome.
    Vuilleumier N; Charbonney E; Fontao L; Alvarez M; Turck N; Sanchez JC; Burkhard PR; Mensi N; Righini M; Reber G; James R; Mach F; Chevrolet JC; Dayer JM; Frostegard J; Roux-Lombard P
    Clin Sci (Lond); 2008 Jul; 115(1):25-33. PubMed ID: 18088236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction.
    Vuilleumier N; Rossier MF; Pagano S; Python M; Charbonney E; Nkoulou R; James R; Reber G; Mach F; Roux-Lombard P
    Eur Heart J; 2010 Apr; 31(7):815-23. PubMed ID: 20176799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients.
    Ashikaga E; Honda H; Suzuki H; Hosaka N; Hirai Y; Sanada D; Nakamura M; Nagai H; Matsumoto K; Kato N; Mukai M; Watanabe M; Takahashi K; Shishido K; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):315-22. PubMed ID: 20609185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
    Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
    Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy.
    Vuilleumier N; Montecucco F; Spinella G; Pagano S; Bertolotto M; Pane B; Pende A; Galan K; Roux-Lombard P; Combescure C; Dallegri F; Mach F; Palombo D
    Thromb Haemost; 2013 Apr; 109(4):706-15. PubMed ID: 23364307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation.
    Santos AO; Fonseca FA; Fischer SM; Monteiro CM; Brandão SA; Póvoa RM; Bombig MT; Carvalho AC; Monteiro AM; Ramos E; Gidlund M; Figueiredo Neto AM; Izar MC
    Clin Chim Acta; 2009 Aug; 406(1-2):113-8. PubMed ID: 19523463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus.
    O'Neill SG; Giles I; Lambrianides A; Manson J; D'Cruz D; Schrieber L; March LM; Latchman DS; Isenberg DA; Rahman A
    Arthritis Rheum; 2010 Mar; 62(3):845-54. PubMed ID: 20131231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
    Lobo J; Santos F; Grosso D; Lima R; Barreira AL; Leite M; Mafra D; Abdalla DS
    Nephron Clin Pract; 2008; 108(4):c298-304. PubMed ID: 18434752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory cytokines and malnutrition as related to risk for cardiovascular disease in hemodialysis patients.
    Perunicic-Pekovic G; Pljesa S; Rasic-Milutinovic Z; Stankovic S; Ilic M; Maletic R
    Can J Physiol Pharmacol; 2008 Apr; 86(4):205-9. PubMed ID: 18418430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population. Results from the CoLaus study.
    Antiochos P; Marques-Vidal P; Virzi J; Pagano S; Satta N; Bastardot F; Hartley O; Montecucco F; Mach F; Waeber G; Vollenweider P; Vuilleumier N
    Thromb Haemost; 2016 Sep; 116(4):764-71. PubMed ID: 27384400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival.
    Snaedal S; Heimbürger O; Qureshi AR; Danielsson A; Wikström B; Fellström B; Fehrman-Ekholm I; Carrero JJ; Alvestrand A; Stenvinkel P; Bárány P
    Am J Kidney Dis; 2009 Jun; 53(6):1024-33. PubMed ID: 19394732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there any relationship between serum levels of interleukin-10 and atherosclerosis in hemodialysis patients?
    Seyrek N; Karayaylali I; Balal M; Paydas S; Aikimbaev K; Cetiner S; Seydaoglu G
    Scand J Urol Nephrol; 2005; 39(5):405-9. PubMed ID: 16257843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-ApoA-1 IgG serum levels predict worse poststroke outcomes.
    Carbone F; Satta N; Montecucco F; Virzi J; Burger F; Roth A; Roversi G; Tamborino C; Casetta I; Seraceni S; Trentini A; Padroni M; Dallegri F; Lalive PH; Mach F; Fainardi E; Vuilleumier N
    Eur J Clin Invest; 2016 Sep; 46(9):805-17. PubMed ID: 27490973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity.
    Vuilleumier N; Bratt J; Alizadeh R; Jogestrand T; Hafström I; Frostegård J
    Scand J Rheumatol; 2010 Nov; 39(6):447-53. PubMed ID: 20604674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that C-reactive protein or IL-6 are not surrogates for all inflammatory cardiovascular risk factors in hemodialysis patients.
    Kaysen GA; Levin NW; Mitch WE; Chapman AL; Kubala L; Eiserich JP
    Blood Purif; 2006; 24(5-6):508-16. PubMed ID: 17077623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.